NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?

Eli Lilly (LLY) and Novo Nordisk (NVO) continue to dominate the rapidly expanding GLP-1 market, with Lilly demonstrating stronger recent performance and outlook. Lilly's Cardiometabolic Health segment, propelled by Mounjaro and Zepbound, reported $9.2 billion in Q1 2025 sales and projects significantly higher 2025 sales and EPS growth, driven by manufacturing scale-up and pipeline diversification. In contrast, Novo Nordisk, despite $10.4 billion in Q1 GLP-1 sales, faces headwinds including disappointing late-stage data for its next-gen obesity candidate, a leadership transition, and a significant year-to-date stock decline. This divergence, alongside increasing competition in the projected $100 billion obesity market, leads to a preference for Lilly as the stronger investment, despite its higher valuation, given NVO's recent setbacks and uncertainty.

Analysis

Eli Lilly (LLY) and Novo Nordisk (NVO) are exhibiting divergent performance trajectories despite their shared dominance in the GLP-1 market. While Novo Nordisk posted higher Q1 2025 sales in its core Diabetes and Obesity segment at $10.4 billion versus Lilly's $9.2 billion Cardiometabolic Health segment, forward-looking indicators favor Lilly. Lilly projects significantly stronger growth for 2025, with expected increases of 33.03% in sales and 68.98% in EPS, dwarfing NVO's respective forecasts of 18.94% and 18.90%. This is further supported by rising 2026 EPS estimates for LLY, while NVO's have declined. Lilly's momentum is fueled by the rapid growth of Mounjaro and Zepbound, which generated a combined $5 billion in Q1, and a more diversified portfolio, with its key segment accounting for 72% of total revenue compared to NVO's highly concentrated 94%.

Conversely, Novo Nordisk faces multiple headwinds that have contributed to its stock's 21.3% year-to-date decline. These include disappointing late-stage trial data for its next-generation obesity candidate, CagriSema, a pending CEO transition creating leadership uncertainty, and the termination of a distribution partnership with Hims & Hers. While the selection of Wegovy as a preferred therapy by CVS Caremark provides a partial offset, the superior weight-loss data from Lilly’s Zepbound presents a direct market share threat. Although NVO trades at a lower forward P/E of 16.05 versus LLY's 30.21 and offers a higher dividend yield of 2.42%, the combination of clinical setbacks, management instability, and intensifying competition from emerging players like Amgen and Viking Therapeutics currently weighs heavily on its outlook.

Key Decisions for Investors

• Given Eli Lilly's robust growth projections, rising 2026 earnings estimates, and a more diversified revenue base, investors may justify its premium valuation in exchange for what appears to be a clearer growth trajectory.
• Investors in Novo Nordisk should monitor for key catalysts that could reverse the negative sentiment, such as a successful CEO appointment, positive pipeline developments beyond CagriSema, and evidence of sustained market share for Wegovy against Zepbound.
• The progression of GLP-1 candidates from competitors like Amgen and Viking Therapeutics into late-stage trials represents a material long-term risk to the duopoly, and portfolio allocations should account for potential future market share erosion for both LLY and NVO.
• Despite NVO's lower valuation and higher dividend yield, the confluence of a significant stock price decline, disappointing clinical news, and leadership uncertainty suggests a cautious or underweight stance may be prudent until these risks are resolved.